TY - BOOK AU - Friedman, F. L. AU - Furberg, C. D. AU - DeMets, D. L. PY - 2010 DA - 2010// TI - Fundamentals of clinical trials PB - Springer CY - New York UR - https://doi.org/10.1007/978-1-4419-1586-3 DO - 10.1007/978-1-4419-1586-3 ID - Friedman2010 ER - TY - JOUR AU - Shih, W. J. PY - 2006 DA - 2006// TI - Plan to be flexible: a commentary on adaptive designs JO - Biometrical J VL - 48 UR - https://doi.org/10.1002/bimj.200610241 DO - 10.1002/bimj.200610241 ID - Shih2006 ER - TY - STD TI - Berry Consultants. What is adaptive design? 2016. http://www.berryconsultants.com/adaptive-designs. Accessed 7 Jul 2017. UR - http://www.berryconsultants.com/adaptive-designs ID - ref3 ER - TY - JOUR AU - Campbell, G. PY - 2013 DA - 2013// TI - Similarities and differences of Bayesian designs and adaptive designs for medical devices: a regulatory view JO - Stat Biopharm Res VL - 5 UR - https://doi.org/10.1080/19466315.2013.846873 DO - 10.1080/19466315.2013.846873 ID - Campbell2013 ER - TY - BOOK AU - Chow, S. C. AU - Chang, M. PY - 2012 DA - 2012// TI - Adaptive design methods in clinical trials PB - Hall/CRC CY - Boca Raton ID - Chow2012 ER - TY - JOUR AU - Morgan, C. C. PY - 2003 DA - 2003// TI - Sample size re-estimation in group-sequential response-adaptive clinical trials JO - Stat Med VL - 22 UR - https://doi.org/10.1002/sim.1677 DO - 10.1002/sim.1677 ID - Morgan2003 ER - TY - JOUR AU - Parmar, M. K. B. AU - Barthel, F. M. S. AU - Sydes, M. AU - Langley, R. AU - Kaplan, R. AU - Eisenhauer, E. PY - 2008 DA - 2008// TI - Speeding up the evaluation of new agents in cancer JO - J Natl Cancer Inst VL - 100 UR - https://doi.org/10.1093/jnci/djn267 DO - 10.1093/jnci/djn267 ID - Parmar2008 ER - TY - JOUR AU - Zohar, S. AU - Chevret, S. PY - 2007 DA - 2007// TI - Recent developments in adaptive designs for phase I/II dose-finding studies JO - J Biopharm Stat VL - 17 UR - https://doi.org/10.1080/10543400701645116 DO - 10.1080/10543400701645116 ID - Zohar2007 ER - TY - JOUR AU - Sverdlov, O. AU - Wong, W. K. PY - 2014 DA - 2014// TI - Novel statistical designs for phase I/II and phase II clinical trials with dose-finding objectives JO - Ther Innov Regul Sci VL - 48 UR - https://doi.org/10.1177/2168479014523765 DO - 10.1177/2168479014523765 ID - Sverdlov2014 ER - TY - JOUR AU - Maca, J. AU - Bhattacharya, S. AU - Dragalin, V. AU - Gallo, P. AU - Krams, M. PY - 2006 DA - 2006// TI - Adaptive seamless phase II/III designs—background, operational aspects, and examples JO - Drug Inf J VL - 40 UR - https://doi.org/10.1177/216847900604000412 DO - 10.1177/216847900604000412 ID - Maca2006 ER - TY - JOUR AU - Stallard, N. AU - Todd, S. PY - 2011 DA - 2011// TI - Seamless phase II/III designs JO - Stat Methods Med Res VL - 20 UR - https://doi.org/10.1177/0962280210379035 DO - 10.1177/0962280210379035 ID - Stallard2011 ER - TY - JOUR AU - Chow, S. C. AU - Chang, M. AU - Pong, A. PY - 2005 DA - 2005// TI - Statistical consideration of adaptive methods in clinical development JO - J Biopharm Stat VL - 15 UR - https://doi.org/10.1081/BIP-200062277 DO - 10.1081/BIP-200062277 ID - Chow2005 ER - TY - JOUR AU - Fleming, T. R. AU - Sharples, K. AU - McCall, J. AU - Moore, A. AU - Rodgers, A. AU - Stewart, R. PY - 2008 DA - 2008// TI - Maintaining confidentiality of interim data to enhance trial integrity and credibility JO - Clin Trials VL - 5 UR - https://doi.org/10.1177/1740774508089459 DO - 10.1177/1740774508089459 ID - Fleming2008 ER - TY - JOUR AU - Bauer, P. AU - Koenig, F. AU - Brannath, W. AU - Posch, M. PY - 2010 DA - 2010// TI - Selection and bias—two hostile brothers JO - Stat Med VL - 29 ID - Bauer2010 ER - TY - JOUR AU - Posch, M. AU - Maurer, W. AU - Bretz, F. PY - 2011 DA - 2011// TI - Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim JO - Pharm Stat VL - 10 UR - https://doi.org/10.1002/pst.413 DO - 10.1002/pst.413 ID - Posch2011 ER - TY - JOUR AU - Graf, A. C. AU - Bauer, P. PY - 2011 DA - 2011// TI - Maximum inflation of the type 1 error rate when sample size and allocation rate are adapted in a pre-planned interim look JO - Stat Med VL - 30 UR - https://doi.org/10.1002/sim.4230 DO - 10.1002/sim.4230 ID - Graf2011 ER - TY - JOUR AU - Graf, A. C. AU - Bauer, P. AU - Glimm, E. AU - Koenig, F. PY - 2014 DA - 2014// TI - Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications JO - Biometrical J VL - 56 UR - https://doi.org/10.1002/bimj.201300153 DO - 10.1002/bimj.201300153 ID - Graf2014 ER - TY - JOUR AU - Magirr, D. AU - Jaki, T. AU - Posch, M. AU - Klinglmueller, F. PY - 2013 DA - 2013// TI - Simultaneous confidence intervals that are compatible with closed testing in adaptive designs JO - Biometrika VL - 100 UR - https://doi.org/10.1093/biomet/ast035 DO - 10.1093/biomet/ast035 ID - Magirr2013 ER - TY - JOUR AU - Kimani, P. K. AU - Todd, S. AU - Stallard, N. PY - 2014 DA - 2014// TI - A comparison of methods for constructing confidence intervals after phase II/III clinical trials JO - Biometrical J VL - 56 UR - https://doi.org/10.1002/bimj.201300036 DO - 10.1002/bimj.201300036 ID - Kimani2014 ER - TY - JOUR AU - Lorch, U. AU - Berelowitz, K. AU - Ozen, C. AU - Naseem, A. AU - Akuffo, E. AU - Taubel, J. PY - 2012 DA - 2012// TI - The practical application of adaptive study design in early phase clinical trials: a retrospective analysis of time savings JO - Eur J Clin Pharmacol VL - 68 UR - https://doi.org/10.1007/s00228-011-1176-3 DO - 10.1007/s00228-011-1176-3 ID - Lorch2012 ER - TY - JOUR AU - Bauer, P. AU - Bretz, F. AU - Dragalin, V. AU - König, F. AU - Wassmer, G. PY - 2016 DA - 2016// TI - Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls JO - Stat Med VL - 35 UR - https://doi.org/10.1002/sim.6472 DO - 10.1002/sim.6472 ID - Bauer2016 ER - TY - JOUR AU - Lee, J. J. AU - Siu, L. L. PY - 2009 DA - 2009// TI - Dose escalation methods in phase I cancer clinical trials JO - J Natl Cancer Inst VL - 101 UR - https://doi.org/10.1093/jnci/djp079 DO - 10.1093/jnci/djp079 ID - Lee2009 ER - TY - JOUR AU - Chevret, S. PY - 2012 DA - 2012// TI - Bayesian adaptive clinical trials: a dream for statisticians only? JO - Stat Med VL - 31 UR - https://doi.org/10.1002/sim.4363 DO - 10.1002/sim.4363 ID - Chevret2012 ER - TY - JOUR AU - Jaki, T. PY - 2013 DA - 2013// TI - Uptake of novel statistical methods for early-phase clinical studies in the UK public sector JO - Clin Trials VL - 10 UR - https://doi.org/10.1177/1740774512474375 DO - 10.1177/1740774512474375 ID - Jaki2013 ER - TY - JOUR AU - Morgan, C. C. AU - Huyck, S. AU - Jenkins, M. AU - Chen, L. AU - Bedding, A. AU - Coffey, C. S. PY - 2014 DA - 2014// TI - Adaptive design: results of 2012 survey on perception and use JO - Ther Innov Regul Sci VL - 48 UR - https://doi.org/10.1177/2168479014522468 DO - 10.1177/2168479014522468 ID - Morgan2014 ER - TY - JOUR AU - Dimairo, M. AU - Boote, J. AU - Julious, S. A. AU - Nicholl, J. P. AU - Todd, S. PY - 2015 DA - 2015// TI - Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials JO - Trials VL - 16 UR - https://doi.org/10.1186/s13063-015-0958-9 DO - 10.1186/s13063-015-0958-9 ID - Dimairo2015 ER - TY - JOUR AU - Dimairo, M. AU - Julious, S. A. AU - Todd, S. AU - Nicholl, J. P. AU - Boote, J. PY - 2015 DA - 2015// TI - Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials JO - Trials VL - 16 UR - https://doi.org/10.1186/s13063-015-1119-x DO - 10.1186/s13063-015-1119-x ID - Dimairo2015 ER - TY - JOUR AU - Hatfield, I. AU - Allison, A. AU - Flight, L. AU - Julious, S. A. AU - Dimairo, M. PY - 2016 DA - 2016// TI - Adaptive designs undertaken in clinical research: a review of registered clinical trials JO - Trials VL - 17 UR - https://doi.org/10.1186/s13063-016-1273-9 DO - 10.1186/s13063-016-1273-9 ID - Hatfield2016 ER - TY - JOUR AU - Meurer, W. J. AU - Legocki, L. AU - Mawocha, S. AU - Frederiksen, S. M. AU - Guetterman, T. C. AU - Barsan, W. PY - 2016 DA - 2016// TI - Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project JO - Trials VL - 17 UR - https://doi.org/10.1186/s13063-016-1493-z DO - 10.1186/s13063-016-1493-z ID - Meurer2016 ER - TY - JOUR AU - Chaitman, B. R. AU - Pepine, C. J. AU - Parker, J. O. AU - Skopal, J. AU - Chumakova, G. AU - Kuch, J. PY - 2004 DA - 2004// TI - Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial JO - J Am Med Assoc VL - 291 UR - https://doi.org/10.1001/jama.291.3.309 DO - 10.1001/jama.291.3.309 ID - Chaitman2004 ER - TY - JOUR AU - Pushpakom, S. P. AU - Taylor, C. AU - Kolamunnage-Dona, R. AU - Spowart, C. AU - García-Fiñana, M. PY - 2015 DA - 2015// TI - Telmisartan and insulin resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy JO - BMJ Open VL - 5 UR - https://doi.org/10.1136/bmjopen-2015-009566 DO - 10.1136/bmjopen-2015-009566 ID - Pushpakom2015 ER - TY - JOUR AU - Magirr, D. AU - Jaki, T. AU - Whitehead, J. PY - 2012 DA - 2012// TI - A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection JO - Biometrika VL - 99 UR - https://doi.org/10.1093/biomet/ass002 DO - 10.1093/biomet/ass002 ID - Magirr2012 ER - TY - JOUR AU - Giles, F. J. AU - Kantarjian, H. M. AU - Cortes, J. E. AU - Garcia-Manero, G. AU - Verstovsek, S. AU - Faderl, S. PY - 2003 DA - 2003// TI - Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.11.016 DO - 10.1200/JCO.2003.11.016 ID - Giles2003 ER - TY - JOUR AU - Mehta, C. R. AU - Pocock, S. J. PY - 2011 DA - 2011// TI - Adaptive increase in sample size when interim results are promising: a practical guide with examples JO - Stat Med VL - 30 UR - https://doi.org/10.1002/sim.4102 DO - 10.1002/sim.4102 ID - Mehta2011 ER - TY - JOUR AU - Jennison, C. AU - Turnbull, B. W. PY - 2015 DA - 2015// TI - Adaptive sample size modification in clinical trials: start small then ask for more? JO - Stat Med VL - 34 UR - https://doi.org/10.1002/sim.6575 DO - 10.1002/sim.6575 ID - Jennison2015 ER - TY - JOUR AU - Bowden, J. AU - Brannath, W. AU - Glimm, E. PY - 2014 DA - 2014// TI - Empirical Bayes estimation of the selected treatment mean for two-stage drop-the-loser trials: a meta-analytic approach JO - Stat Med VL - 33 UR - https://doi.org/10.1002/sim.5920 DO - 10.1002/sim.5920 ID - Bowden2014 ER - TY - JOUR AU - Mason, A. J. AU - Gonzalez-Maffe, J. AU - Quinn, K. AU - Doyle, N. AU - Legg, K. AU - Norsworthy, P. PY - 2017 DA - 2017// TI - Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment JO - Stat Med VL - 36 UR - https://doi.org/10.1002/sim.7169 DO - 10.1002/sim.7169 ID - Mason2017 ER - TY - STD TI - Wellcome Trust. Joint Global Health Trials scheme. 2017. https://wellcome.ac.uk/funding/joint-global-health-trials-scheme. Accessed 7 Jul 2017. UR - https://wellcome.ac.uk/funding/joint-global-health-trials-scheme ID - ref38 ER - TY - STD TI - National Institutes of Health. NIH Planning Grant Program (R34). 2014. https://grants.nih.gov/grants/funding/r34.htm. Accessed 7 Jul 2017. UR - https://grants.nih.gov/grants/funding/r34.htm ID - ref39 ER - TY - STD TI - European Medicines Agency. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003616.pdf. Accessed 7 Jul 2017. UR - http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003616.pdf ID - ref40 ER - TY - STD TI - US Food & Drug Administration. Adaptive design clinical trials for drugs and biologics: guidance for industry (draft). 2010. https://www.fda.gov/downloads/drugs/guidances/ucm201790.pdf. Accessed 7 Jul 2017. UR - https://www.fda.gov/downloads/drugs/guidances/ucm201790.pdf ID - ref41 ER - TY - STD TI - Food US & Drug Administration. Adaptive designs for medical device clinical studies: guidance for industry and Food and Drug Administration staff.2016. https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm446729.pdf. Accessed 7 Jul 2017. UR - https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm446729.pdf ID - ref42 ER - TY - JOUR AU - Gaydos, B. AU - Koch, A. AU - Miller, F. AU - Posch, M. AU - Vandemeulebroecke, M. AU - Wang, S. J. PY - 2012 DA - 2012// TI - Perspective on adaptive designs: 4 years European Medicines Agency reflection paper, 1 year draft US FDA guidance—where are we now? JO - Clin Investig VL - 2 UR - https://doi.org/10.4155/cli.12.5 DO - 10.4155/cli.12.5 ID - Gaydos2012 ER - TY - JOUR AU - Elsäßer, A. AU - Regnstrom, J. AU - Vetter, T. AU - Koenig, F. AU - Hemmings, R. J. AU - Greco, M. PY - 2014 DA - 2014// TI - Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency JO - Trials VL - 15 UR - https://doi.org/10.1186/1745-6215-15-383 DO - 10.1186/1745-6215-15-383 ID - Elsäßer2014 ER - TY - JOUR AU - DeMets, D. L. AU - Fleming, T. R. PY - 2004 DA - 2004// TI - The independent statistician for data monitoring committees JO - Stat Med VL - 23 UR - https://doi.org/10.1002/sim.1786 DO - 10.1002/sim.1786 ID - DeMets2004 ER - TY - JOUR AU - Gallo, P. PY - 2006 DA - 2006// TI - Operational challenges in adaptive design implementation JO - Pharm Stat VL - 5 UR - https://doi.org/10.1002/pst.221 DO - 10.1002/pst.221 ID - Gallo2006 ER - TY - JOUR AU - Grant, A. M. AU - Altman, D. G. AU - Babiker, A. G. AU - Campbell, M. K. AU - Clemens, F. AU - Darbyshire, J. H. PY - 2005 DA - 2005// TI - A proposed charter for clinical trial data monitoring committees: helping them to do their job well JO - Lancet VL - 365 UR - https://doi.org/10.1016/S0140-6736(05)70939-9 DO - 10.1016/S0140-6736(05)70939-9 ID - Grant2005 ER - TY - JOUR AU - Antonijevic, Z. AU - Gallo, P. AU - Chuang-Stein, C. AU - Dragalin, V. AU - Loewy, J. AU - Menon, S. PY - 2013 DA - 2013// TI - Views on emerging issues pertaining to data monitoring committees for adaptive trials JO - Ther Innov Regul Sci VL - 47 UR - https://doi.org/10.1177/2168479013486996 DO - 10.1177/2168479013486996 ID - Antonijevic2013 ER - TY - JOUR AU - Sanchez-Kam, M. AU - Gallo, P. AU - Loewy, J. AU - Menon, S. AU - Antonijevic, Z. AU - Christensen, J. PY - 2014 DA - 2014// TI - A practical guide to data monitoring committees in adaptive trials JO - Ther Innov Regul Sci VL - 48 UR - https://doi.org/10.1177/2168479013509805 DO - 10.1177/2168479013509805 ID - Sanchez-Kam2014 ER - TY - JOUR AU - DeMets, D. L. AU - Ellenberg, S. S. PY - 2016 DA - 2016// TI - Data monitoring committees—expect the unexpected JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMra1510066 DO - 10.1056/NEJMra1510066 ID - DeMets2016 ER - TY - JOUR AU - Calis, K. A. AU - Archdeacon, P. AU - Bain, R. AU - DeMets, D. AU - Donohue, M. AU - Elzarrad, M. K. PY - 2017 DA - 2017// TI - Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative JO - Clin Trials VL - 14 UR - https://doi.org/10.1177/1740774517707743 DO - 10.1177/1740774517707743 ID - Calis2017 ER - TY - JOUR AU - Conroy, E. J. AU - Harman, N. L. AU - Lane, J. A. AU - Lewis, S. C. AU - Murray, G. AU - Norrie, J. PY - 2015 DA - 2015// TI - Trial steering committees in randomised controlled trials: a survey of registered clinical trials units to establish current practice and experiences JO - Clin Trials VL - 12 UR - https://doi.org/10.1177/1740774515589959 DO - 10.1177/1740774515589959 ID - Conroy2015 ER - TY - JOUR AU - Harman, N. L. AU - Conroy, E. J. AU - Lewis, S. C. AU - Murray, G. AU - Norrie, J. AU - Sydes, M. R. PY - 2015 DA - 2015// TI - Exploring the role and function of trial steering committees: results of an expert panel meeting JO - Trials VL - 16 UR - https://doi.org/10.1186/s13063-015-1125-z DO - 10.1186/s13063-015-1125-z ID - Harman2015 ER - TY - JOUR AU - Daykin, A. AU - Selman, L. E. AU - Cramer, H. AU - McCann, S. AU - Shorter, G. W. AU - Sydes, M. R. PY - 2016 DA - 2016// TI - What are the roles and valued attributes of a trial steering committee? Ethnographic study of eight clinical trials facing challenges JO - Trials VL - 17 UR - https://doi.org/10.1186/s13063-016-1425-y DO - 10.1186/s13063-016-1425-y ID - Daykin2016 ER - TY - JOUR AU - He, W. AU - Gallo, P. AU - Miller, E. AU - Jemiai, Y. AU - Maca, J. AU - Koury, K. PY - 2017 DA - 2017// TI - Addressing challenges and opportunities of ‘less well-understood’ adaptive designs JO - Ther Innov Regul Sci VL - 51 UR - https://doi.org/10.1177/2168479016663265 DO - 10.1177/2168479016663265 ID - He2017 ER - TY - JOUR AU - Zhu, L. AU - Ni, L. AU - Yao, B. PY - 2011 DA - 2011// TI - Group sequential methods and software applications JO - Am Stat VL - 65 UR - https://doi.org/10.1198/tast.2011.10213 DO - 10.1198/tast.2011.10213 ID - Zhu2011 ER - TY - CHAP AU - Tymofyeyev, Y. ED - He, W. ED - Pinheiro, J. ED - Kuznetsova, O. M. PY - 2014 DA - 2014// TI - A review of available software and capabilities for adaptive designs BT - Practical considerations for adaptive trial design and implementation PB - Springer CY - New York ID - Tymofyeyev2014 ER - TY - JOUR AU - Gallo, P. AU - Chuang-Stein, C. AU - Dragalin, V. AU - Gaydos, B. AU - Krams, M. AU - Pinheiro, J. PY - 2006 DA - 2006// TI - Adaptive designs in clinical drug development—an executive summary of the PhRMA Working Group JO - J Biopharm Stat VL - 16 UR - https://doi.org/10.1080/10543400600614742 DO - 10.1080/10543400600614742 ID - Gallo2006 ER - TY - JOUR AU - Quinlan, J. AU - Krams, M. PY - 2006 DA - 2006// TI - Implementing adaptive designs: logistical and operational considerations JO - Drug Inf J VL - 40 UR - https://doi.org/10.1177/216847900604000409 DO - 10.1177/216847900604000409 ID - Quinlan2006 ER - TY - JOUR AU - Chow, S. C. AU - Chang, M. PY - 2008 DA - 2008// TI - Adaptive design methods in clinical trials—a review JO - Orphanet J Rare Dis VL - 3 UR - https://doi.org/10.1186/1750-1172-3-11 DO - 10.1186/1750-1172-3-11 ID - Chow2008 ER - TY - JOUR AU - Bretz, F. AU - Koenig, F. AU - Brannath, W. AU - Glimm, E. AU - Posch, M. PY - 2009 DA - 2009// TI - Adaptive designs for confirmatory clinical trials JO - Stat Med VL - 28 UR - https://doi.org/10.1002/sim.3538 DO - 10.1002/sim.3538 ID - Bretz2009 ER - TY - JOUR AU - Quinlan, J. AU - Gaydos, B. AU - Maca, J. AU - Krams, M. PY - 2010 DA - 2010// TI - Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development JO - Clin Trials VL - 7 UR - https://doi.org/10.1177/1740774510361542 DO - 10.1177/1740774510361542 ID - Quinlan2010 ER - TY - JOUR AU - He, W. AU - Kuznetsova, O. M. AU - Harmer, M. AU - Leahy, C. AU - Anderson, K. AU - Dossin, N. PY - 2012 DA - 2012// TI - Practical considerations and strategies for executing adaptive clinical trials JO - Ther Innov Regul Sci VL - 46 ID - He2012 ER - TY - STD TI - He W, Pinheiro J, Kuznetsova OM. Practical considerations for adaptive trial design and implementation. New York: Springer; 2014. ID - ref64 ER - TY - JOUR AU - Curtin, F. AU - Heritier, S. PY - 2017 DA - 2017// TI - The role of adaptive trial designs in drug development JO - Expert Rev Clin Pharmacol VL - 10 UR - https://doi.org/10.1080/17512433.2017.1321985 DO - 10.1080/17512433.2017.1321985 ID - Curtin2017 ER - TY - JOUR AU - Petroni, G. R. AU - Wages, N. A. AU - Paux, G. AU - Dubois, F. PY - 2017 DA - 2017// TI - Implementation of adaptive methods in early-phase clinical trials JO - Stat Med VL - 36 UR - https://doi.org/10.1002/sim.6910 DO - 10.1002/sim.6910 ID - Petroni2017 ER - TY - JOUR AU - Sydes, M. R. AU - Parmar, M. K. B. AU - James, N. D. AU - Clarke, N. W. AU - Dearnaley, D. P. AU - Mason, M. D. PY - 2009 DA - 2009// TI - Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial JO - Trials VL - 10 UR - https://doi.org/10.1186/1745-6215-10-39 DO - 10.1186/1745-6215-10-39 ID - Sydes2009 ER - TY - JOUR AU - Spencer, K. AU - Colvin, K. AU - Braunecker, B. AU - Brackman, M. AU - Ripley, J. AU - Hines, P. PY - 2012 DA - 2012// TI - Operational challenges and solutions with implementation of an adaptive seamless phase 2/3 study JO - J Diabetes Sci Technol VL - 6 UR - https://doi.org/10.1177/193229681200600608 DO - 10.1177/193229681200600608 ID - Spencer2012 ER - TY - JOUR AU - Miller, E. AU - Gallo, P. AU - He, W. AU - Kammerman, L. A. AU - Koury, K. AU - Maca, J. PY - 2017 DA - 2017// TI - DIA’s Adaptive Design Scientific Working Group (ADSWG): best practices case studies for ‘less well-understood’ adaptive designs JO - Ther Innov Regul Sci VL - 51 UR - https://doi.org/10.1177/2168479016665434 DO - 10.1177/2168479016665434 ID - Miller2017 ER - TY - JOUR AU - Schäfer, H. AU - Timmesfeld, N. AU - Müller, H. H. PY - 2006 DA - 2006// TI - An overview of statistical approaches for adaptive designs and design modifications JO - Biom J VL - 48 UR - https://doi.org/10.1002/bimj.200510234 DO - 10.1002/bimj.200510234 ID - Schäfer2006 ER - TY - BOOK AU - Wassmer, G. AU - Brannath, W. PY - 2016 DA - 2016// TI - Group sequential and confirmatory adaptive designs in clinical trials PB - Springer CY - Heidelberg UR - https://doi.org/10.1007/978-3-319-32562-0 DO - 10.1007/978-3-319-32562-0 ID - Wassmer2016 ER - TY - JOUR AU - Ellenberg, S. S. AU - DeMets, D. L. AU - Fleming, T. R. PY - 2010 DA - 2010// TI - Bias and trials stopped early for benefit JO - J Am Med Assoc VL - 304 UR - https://doi.org/10.1001/jama.2010.933 DO - 10.1001/jama.2010.933 ID - Ellenberg2010 ER - TY - CHAP AU - Jennison, C. AU - Turnbull, B. W. PY - 2000 DA - 2000// TI - Analysis following a sequential test BT - Group sequential methods with applications to clinical trials PB - Hall/CRC CY - Boca Raton ID - Jennison2000 ER - TY - JOUR AU - Emerson, S. S. AU - Fleming, T. R. PY - 1990 DA - 1990// TI - Parameter estimation following group sequential hypothesis testing JO - Biometrika VL - 77 UR - https://doi.org/10.1093/biomet/77.4.875 DO - 10.1093/biomet/77.4.875 ID - Emerson1990 ER - TY - JOUR AU - Liu, A. AU - Hall, W. J. PY - 1999 DA - 1999// TI - Unbiased estimation following a group sequential test JO - Biometrika VL - 86 UR - https://doi.org/10.1093/biomet/86.1.71 DO - 10.1093/biomet/86.1.71 ID - Liu1999 ER - TY - JOUR AU - Bowden, J. AU - Glimm, E. PY - 2008 DA - 2008// TI - Unbiased estimation of selected treatment means in two-stage trials JO - Biometrical J VL - 50 UR - https://doi.org/10.1002/bimj.200810442 DO - 10.1002/bimj.200810442 ID - Bowden2008 ER - TY - JOUR AU - Bowden, J. AU - Glimm, E. PY - 2014 DA - 2014// TI - Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials JO - Biometrical J VL - 56 UR - https://doi.org/10.1002/bimj.201200245 DO - 10.1002/bimj.201200245 ID - Bowden2014 ER - TY - JOUR AU - Whitehead, J. PY - 1986 DA - 1986// TI - On the bias of maximum likelihood estimation following a sequential test JO - Biometrika VL - 73 UR - https://doi.org/10.1093/biomet/73.3.573 DO - 10.1093/biomet/73.3.573 ID - Whitehead1986 ER - TY - JOUR AU - Jovic, G. AU - Whitehead, J. PY - 2010 DA - 2010// TI - An exact method for analysis following a two-stage phase II cancer clinical trial JO - Stat Med VL - 29 UR - https://doi.org/10.1002/sim.3837 DO - 10.1002/sim.3837 ID - Jovic2010 ER - TY - JOUR AU - Carreras, M. AU - Brannath, W. PY - 2013 DA - 2013// TI - Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection JO - Stat Med VL - 32 UR - https://doi.org/10.1002/sim.5463 DO - 10.1002/sim.5463 ID - Carreras2013 ER - TY - JOUR AU - Brueckner, M. AU - Titman, A. AU - Jaki, T. PY - 2017 DA - 2017// TI - Estimation in multi-arm two-stage trials with treatment selection and time-to-event endpoint JO - Stat Med VL - 36 UR - https://doi.org/10.1002/sim.7367 DO - 10.1002/sim.7367 ID - Brueckner2017 ER - TY - JOUR AU - Bowden, J. AU - Wason, J. PY - 2012 DA - 2012// TI - Identifying combined design and analysis procedures in two-stage trials with a binary end point JO - Stat Med VL - 31 UR - https://doi.org/10.1002/sim.5468 DO - 10.1002/sim.5468 ID - Bowden2012 ER - TY - JOUR AU - Choodari-Oskooei, B. AU - Parmar, M. K. AU - Royston, P. AU - Bowden, J. PY - 2013 DA - 2013// TI - Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome JO - Trials VL - 14 UR - https://doi.org/10.1186/1745-6215-14-23 DO - 10.1186/1745-6215-14-23 ID - Choodari-Oskooei2013 ER - TY - BOOK AU - Efron, B. AU - Tibshirani, R. J. PY - 1993 DA - 1993// TI - An introduction to the bootstrap PB - Hall/CRC CY - Boca Raton UR - https://doi.org/10.1007/978-1-4899-4541-9 DO - 10.1007/978-1-4899-4541-9 ID - Efron1993 ER - TY - JOUR AU - Gao, P. AU - Liu, L. AU - Mehta, C. PY - 2013 DA - 2013// TI - Exact inference for adaptive group sequential designs JO - Stat Med VL - 32 UR - https://doi.org/10.1002/sim.5847 DO - 10.1002/sim.5847 ID - Gao2013 ER - TY - JOUR AU - Kimani, P. K. AU - Todd, S. AU - Stallard, N. PY - 2015 DA - 2015// TI - Estimation after subpopulation selection in adaptive seamless trials JO - Stat Med VL - 34 UR - https://doi.org/10.1002/sim.6506 DO - 10.1002/sim.6506 ID - Kimani2015 ER - TY - JOUR AU - Jennison, C. AU - Turnbull, B. W. PY - 1989 DA - 1989// TI - Interim analyses: the repeated confidence interval approach JO - J R Stat Soc Series B Stat Methodol VL - 51 ID - Jennison1989 ER - TY - JOUR AU - Proschan, M. A. AU - Hunsberger, S. A. PY - 1995 DA - 1995// TI - Designed extension of studies based on conditional power JO - Biometrics VL - 51 UR - https://doi.org/10.2307/2533262 DO - 10.2307/2533262 ID - Proschan1995 ER - TY - JOUR AU - Kieser, M. AU - Friede, T. PY - 2003 DA - 2003// TI - Simple procedures for blinded sample size adjustment that do not affect the type I error rate JO - Stat Med VL - 22 UR - https://doi.org/10.1002/sim.1585 DO - 10.1002/sim.1585 ID - Kieser2003 ER - TY - JOUR AU - żebrowska, M. AU - Posch, M. AU - Magirr, D. PY - 2016 DA - 2016// TI - Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels JO - Stat Med VL - 35 UR - https://doi.org/10.1002/sim.6848 DO - 10.1002/sim.6848 ID - żebrowska2016 ER - TY - JOUR AU - Bratton, D. J. AU - Parmar, M. K. B. AU - Phillips, P. P. J. AU - Choodari-Oskooei, B. PY - 2016 DA - 2016// TI - Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes JO - Trials VL - 17 UR - https://doi.org/10.1186/s13063-016-1382-5 DO - 10.1186/s13063-016-1382-5 ID - Bratton2016 ER - TY - JOUR AU - Glimm, E. AU - Maurer, W. AU - Bretz, F. PY - 2010 DA - 2010// TI - Hierarchical testing of multiple endpoints in group-sequential trials JO - Stat Med VL - 29 ID - Glimm2010 ER - TY - JOUR AU - Ye, Y. AU - Li, A. AU - Liu, L. AU - Yao, B. PY - 2013 DA - 2013// TI - A group sequential Holm procedure with multiple primary endpoints JO - Stat Med VL - 32 UR - https://doi.org/10.1002/sim.5700 DO - 10.1002/sim.5700 ID - Ye2013 ER - TY - CHAP AU - Maurer, W. AU - Branson, M. AU - Posch, M. ED - Dmitrienko, A. ED - Tamhane, A. C. ED - Bretz, F. PY - 2010 DA - 2010// TI - Adaptive designs and confirmatory hypothesis testing BT - Multiple testing problems in pharmaceutical statistics PB - Hall/CRC CY - Boca Raton ID - Maurer2010 ER - TY - JOUR AU - Posch, M. AU - Koenig, F. AU - Branson, M. AU - Brannath, W. AU - Dunger-Baldauf, C. AU - Bauer, P. PY - 2005 DA - 2005// TI - Testing and estimation in flexible group sequential designs with adaptive treatment selection JO - Stat Med VL - 24 UR - https://doi.org/10.1002/sim.2389 DO - 10.1002/sim.2389 ID - Posch2005 ER - TY - JOUR AU - Wason, J. M. S. AU - Stecher, L. AU - Mander, A. P. PY - 2014 DA - 2014// TI - Correcting for multiple-testing in multi-arm trials: is it necessary and is it done? JO - Trials VL - 15 UR - https://doi.org/10.1186/1745-6215-15-364 DO - 10.1186/1745-6215-15-364 ID - Wason2014 ER - TY - JOUR AU - Wang, S. J. AU - Hung, H. M. J. AU - O’Neill, R. PY - 2011 DA - 2011// TI - Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program JO - J Biopharm Stat VL - 21 UR - https://doi.org/10.1080/10543406.2011.552878 DO - 10.1080/10543406.2011.552878 ID - Wang2011 ER - TY - STD TI - European Medicines Agency. Guideline on multiplicity issues in clinical trials (draft). 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/03/WC500224998.pdf. Accessed 7 Jul 2017. UR - http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/03/WC500224998.pdf ID - ref98 ER - TY - STD TI - US Food & Drug Administration. Multiple endpoints in clinical trials: guidance for industry (draft). 2017. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM536750.pdf. Accessed 7 Jul 2017. UR - https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM536750.pdf ID - ref99 ER - TY - BOOK AU - Berry, S. M. AU - Carlin, B. P. AU - Lee, J. J. AU - Müller, P. PY - 2010 DA - 2010// TI - Bayesian adaptive methods for clinical trials PB - Hall/CRC CY - Boca Raton UR - https://doi.org/10.1201/EBK1439825488 DO - 10.1201/EBK1439825488 ID - Berry2010 ER - TY - BOOK AU - Chevret, S. PY - 2006 DA - 2006// TI - Statistical methods for dose-finding experiments PB - Wiley CY - Chichester UR - https://doi.org/10.1002/0470861258 DO - 10.1002/0470861258 ID - Chevret2006 ER - TY - BOOK AU - Cheung, Y. K. PY - 2011 DA - 2011// TI - Dose finding by the continual reassessment method PB - Hall/CRC CY - Boca Raton UR - https://doi.org/10.1201/b10783 DO - 10.1201/b10783 ID - Cheung2011 ER - TY - JOUR AU - Thall, P. F. AU - Wathen, J. K. PY - 2007 DA - 2007// TI - Practical Bayesian adaptive randomisation in clinical trials JO - Eur J Cancer VL - 43 UR - https://doi.org/10.1016/j.ejca.2007.01.006 DO - 10.1016/j.ejca.2007.01.006 ID - Thall2007 ER - TY - JOUR AU - Jansen, J. O. AU - Pallmann, P. AU - MacLennan, G. AU - Campbell, M. K. PY - 2017 DA - 2017// TI - Bayesian clinical trial designs: another option for trauma trials? JO - J Trauma Acute Care Surg VL - 83 UR - https://doi.org/10.1097/TA.0000000000001638 DO - 10.1097/TA.0000000000001638 ID - Jansen2017 ER - TY - JOUR AU - Kimani, P. K. AU - Glimm, E. AU - Maurer, W. AU - Hutton, J. L. AU - Stallard, N. PY - 2012 DA - 2012// TI - Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods JO - Stat Med VL - 31 UR - https://doi.org/10.1002/sim.5326 DO - 10.1002/sim.5326 ID - Kimani2012 ER - TY - JOUR AU - Liu, S. AU - Lee, J. J. PY - 2015 DA - 2015// TI - An overview of the design and conduct of the BATTLE trials JO - Chin Clin Oncol VL - 4 ID - Liu2015 ER - TY - JOUR AU - Cheng, Y. AU - Shen, Y. PY - 2005 DA - 2005// TI - Bayesian adaptive designs for clinical trials JO - Biometrika VL - 92 UR - https://doi.org/10.1093/biomet/92.3.633 DO - 10.1093/biomet/92.3.633 ID - Cheng2005 ER - TY - JOUR AU - Lewis, R. J. AU - Lipsky, A. M. AU - Berry, D. A. PY - 2007 DA - 2007// TI - Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation JO - Clin Trials VL - 4 UR - https://doi.org/10.1177/1740774506075764 DO - 10.1177/1740774506075764 ID - Lewis2007 ER - TY - JOUR AU - Ventz, S. AU - Trippa, L. PY - 2015 DA - 2015// TI - Bayesian designs and the control of frequentist characteristics: a practical solution JO - Biometrics VL - 71 UR - https://doi.org/10.1111/biom.12226 DO - 10.1111/biom.12226 ID - Ventz2015 ER - TY - JOUR AU - Emerson, S. S. AU - Kittelson, J. M. AU - Gillen, D. L. PY - 2007 DA - 2007// TI - Frequentist evaluation of group sequential clinical trial designs JO - Stat Med VL - 26 UR - https://doi.org/10.1002/sim.2901 DO - 10.1002/sim.2901 ID - Emerson2007 ER - TY - JOUR AU - Emerson, S. S. AU - Kittelson, J. M. AU - Gillen, D. L. PY - 2007 DA - 2007// TI - Bayesian evaluation of group sequential clinical trial designs JO - Stat Med VL - 26 UR - https://doi.org/10.1002/sim.2640 DO - 10.1002/sim.2640 ID - Emerson2007 ER - TY - JOUR AU - Gsponer, T. AU - Gerber, F. AU - Bornkamp, B. AU - Ohlssen, D. AU - Vandemeulebroecke, M. AU - Schmidli, H. PY - 2014 DA - 2014// TI - A practical guide to Bayesian group sequential designs JO - Pharm Stat VL - 13 UR - https://doi.org/10.1002/pst.1593 DO - 10.1002/pst.1593 ID - Gsponer2014 ER - TY - JOUR AU - Stallard, N. AU - Whitehead, J. AU - Cleall, S. PY - 2005 DA - 2005// TI - Decision-making in a phase II clinical trial: a new approach combining Bayesian and frequentist concepts JO - Pharm Stat VL - 4 UR - https://doi.org/10.1002/pst.164 DO - 10.1002/pst.164 ID - Stallard2005 ER - TY - JOUR AU - Dong, G. AU - Shih, W. J. AU - Moore, D. AU - Quan, H. AU - Marcella, S. PY - 2012 DA - 2012// TI - A Bayesian-frequentist two-stage single-arm phase II clinical trial design JO - Stat Med VL - 31 UR - https://doi.org/10.1002/sim.5330 DO - 10.1002/sim.5330 ID - Dong2012 ER - TY - JOUR AU - Hartley, A. M. PY - 2012 DA - 2012// TI - Adaptive blinded sample size adjustment for comparing two normal means—a mostly Bayesian approach JO - Pharm Stat VL - 11 UR - https://doi.org/10.1002/pst.538 DO - 10.1002/pst.538 ID - Hartley2012 ER - TY - JOUR AU - Gallo, P. PY - 2006 DA - 2006// TI - Confidentiality and trial integrity issues for adaptive designs JO - Drug Inf J VL - 40 UR - https://doi.org/10.1177/216847900604000410 DO - 10.1177/216847900604000410 ID - Gallo2006 ER - TY - JOUR AU - Broglio, K. R. AU - Stivers, D. N. AU - Berry, D. A. PY - 2014 DA - 2014// TI - Predicting clinical trial results based on announcements of interim analyses JO - Trials VL - 15 UR - https://doi.org/10.1186/1745-6215-15-73 DO - 10.1186/1745-6215-15-73 ID - Broglio2014 ER - TY - JOUR AU - Chow, S. C. AU - Corey, R. AU - Lin, M. PY - 2012 DA - 2012// TI - On the independence of data monitoring committee in adaptive design clinical trials JO - J Biopharm Stat VL - 22 UR - https://doi.org/10.1080/10543406.2012.676536 DO - 10.1080/10543406.2012.676536 ID - Chow2012 ER - TY - JOUR AU - Friede, T. AU - Henderson, R. PY - 2009 DA - 2009// TI - Exploring changes in treatment effects across design stages in adaptive trials JO - Pharm Stat VL - 8 UR - https://doi.org/10.1002/pst.332 DO - 10.1002/pst.332 ID - Friede2009 ER - TY - JOUR AU - Gallo, P. AU - Chuang-Stein, C. PY - 2009 DA - 2009// TI - What should be the role of homogeneity testing in adaptive trials? JO - Pharm Stat VL - 8 UR - https://doi.org/10.1002/pst.342 DO - 10.1002/pst.342 ID - Gallo2009 ER - TY - JOUR AU - Gonnermann, A. AU - Framke, T. AU - Großhennig, A. AU - Koch, A. PY - 2015 DA - 2015// TI - No solution yet for combining two independent studies in the presence of heterogeneity JO - Stat Med VL - 34 UR - https://doi.org/10.1002/sim.6473 DO - 10.1002/sim.6473 ID - Gonnermann2015 ER - TY - JOUR AU - Parker, R. A. PY - 2010 DA - 2010// TI - Testing for qualitative interactions between stages in an adaptive study JO - Stat Med VL - 29 UR - https://doi.org/10.1002/sim.3757 DO - 10.1002/sim.3757 ID - Parker2010 ER - TY - JOUR AU - Wang, S. J. AU - Brannath, W. AU - Brückner, M. AU - Hung, H. M. J. AU - Koch, A. PY - 2013 DA - 2013// TI - Unblinded adaptive statistical information design based on clinical endpoint or biomarker JO - Stat Biopharm Res VL - 5 UR - https://doi.org/10.1080/19466315.2013.791639 DO - 10.1080/19466315.2013.791639 ID - Wang2013 ER - TY - JOUR AU - Jüni, P. AU - Altman, D. G. AU - Egger, M. PY - 2001 DA - 2001// TI - Systematic reviews in health care: assessing the quality of controlled clinical trials JO - BMJ VL - 323 UR - https://doi.org/10.1136/bmj.323.7303.42 DO - 10.1136/bmj.323.7303.42 ID - Jüni2001 ER - TY - JOUR AU - Schulz, K. F. AU - Altman, D. G. AU - Moher, D. PY - 2010 DA - 2010// TI - CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials JO - BMJ VL - 340 UR - https://doi.org/10.1136/bmj.c332 DO - 10.1136/bmj.c332 ID - Schulz2010 ER - TY - JOUR AU - Bauer, P. AU - Einfalt, J. PY - 2006 DA - 2006// TI - Application of adaptive designs—a review JO - Biometrical J VL - 48 UR - https://doi.org/10.1002/bimj.200510204 DO - 10.1002/bimj.200510204 ID - Bauer2006 ER - TY - STD TI - Detry MA, Lewis RJ, Broglio KR, Connor JT, Berry SM, Berry DA. Standards for the design, conduct, and evaluation of adaptive randomized clinical trials. Washington: Patient-Centered Outcomes Research Institute; 2012. http://www.pcori.org/assets/Standards-for-the-Design-Conduct-and-Evaluation-of-Adaptive-Randomized-Clinical-Trials.pdf. Accessed 7 Jul 2017. UR - http://www.pcori.org/assets/Standards-for-the-Design-Conduct-and-Evaluation-of-Adaptive-Randomized-Clinical-Trials.pdf ID - ref127 ER - TY - JOUR AU - Lorch, U. AU - O’Kane, M. AU - Taubel, J. PY - 2014 DA - 2014// TI - Three steps to writing adaptive study protocols in the early phase clinical development of new medicines JO - BMC Med Res Methodol VL - 14 UR - https://doi.org/10.1186/1471-2288-14-84 DO - 10.1186/1471-2288-14-84 ID - Lorch2014 ER - TY - JOUR AU - Stevely, A. AU - Dimairo, M. AU - Todd, S. AU - Julious, S. A. AU - Nicholl, J. AU - Hind, D. PY - 2015 DA - 2015// TI - An investigation of the shortcomings of the CONSORT 2010 statement for the reporting of group sequential randomised controlled trials: a methodological systematic review JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0141104 DO - 10.1371/journal.pone.0141104 ID - Stevely2015 ER - TY - STD TI - Dimairo M. The utility of adaptive designs in publicly funded confirmatory trials. 2016. http://etheses.whiterose.ac.uk/13981. Accessed 7 Jul 2017. UR - http://etheses.whiterose.ac.uk/13981 ID - ref130 ER - TY - JOUR AU - Nie, L. AU - Rubin, E. H. AU - Mehrotra, N. AU - Pinheiro, J. AU - Fernandes, L. L. AU - Roy, A. PY - 2016 DA - 2016// TI - Rendering the 3 + 3 design to rest: more efficient approaches to oncology dose-finding trials in the era of targeted therapy JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2644 DO - 10.1158/1078-0432.CCR-15-2644 ID - Nie2016 ER - TY - STD TI - Adaptive Designs Working Group of the MRC Network of Hubs for Trials Methodology Research. A quick guide why not to use A+B designs. 2016. https://www.methodologyhubs.mrc.ac.uk/files/6814/6253/2385/A_quick_guide_why_not_to_use_AB_designs.pdf. Accessed 7 Jul 2017. UR - https://www.methodologyhubs.mrc.ac.uk/files/6814/6253/2385/A_quick_guide_why_not_to_use_AB_designs.pdf ID - ref132 ER - TY - JOUR AU - Cuffe, R. L. AU - Lawrence, D. AU - Stone, A. AU - Vandemeulebroecke, M. PY - 2014 DA - 2014// TI - When is a seamless study desirable? Case studies from different pharmaceutical sponsors JO - Pharm Stat VL - 13 UR - https://doi.org/10.1002/pst.1622 DO - 10.1002/pst.1622 ID - Cuffe2014 ER - TY - JOUR AU - Jaki, T. PY - 2015 DA - 2015// TI - Multi-arm clinical trials with treatment selection: what can be gained and at what price? JO - Clin Investig VL - 5 UR - https://doi.org/10.4155/cli.15.13 DO - 10.4155/cli.15.13 ID - Jaki2015 ER - TY - JOUR AU - Coffey, C. S. AU - Kairalla, J. A. PY - 2008 DA - 2008// TI - Adaptive clinical trials: progress and challenges JO - Drugs R D VL - 9 UR - https://doi.org/10.2165/00126839-200809040-00003 DO - 10.2165/00126839-200809040-00003 ID - Coffey2008 ER - TY - STD TI - Cole M, Stocken D, Yap C. A pragmatic approach to the design and calibration of a Bayesian CRM dose finding trial. Trials. 2015;16 Suppl2:P210. ID - ref136 ER - TY - JOUR AU - Yap, C. AU - Billingham, L. J. AU - Cheung, Y. K. AU - Craddock, C. AU - O’Quigley, J. PY - 2017 DA - 2017// TI - Dose transition pathways: the missing link between complex dose-finding designs and simple decision making JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-0582 DO - 10.1158/1078-0432.CCR-17-0582 ID - Yap2017 ER - TY - STD TI - Yap C, Craddock C, Collins G, Khan J, Siddique S, Billingham L. Implementation of adaptive dose-finding designs in two early phase haematological trials: clinical, operational, and methodological challenges. Trials. 2013;14 Suppl 1:O75. ID - ref138 ER - TY - STD TI - Fisher AJ, Yonan N, Mascaro J, Marczin N, Tsui S, Simon A, et al. A study of donor ex-vivo lung perfusion in UK lung transplantation (DEVELOP-UK). J Heart Lung Transplant. 2016;35 Suppl 4:S80. ID - ref139 ER - TY - JOUR AU - Sydes, M. R. AU - Parmar, M. K. B. AU - Mason, M. D. AU - Clarke, N. W. AU - Amos, C. AU - Anderson, J. PY - 2012 DA - 2012// TI - Flexible trial design in practice—stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial JO - Trials VL - 13 UR - https://doi.org/10.1186/1745-6215-13-168 DO - 10.1186/1745-6215-13-168 ID - Sydes2012 ER - TY - STD TI - Gaunt P, Mehanna H, Yap C. The design of a multi-arm multi-stage (MAMS) phase III randomised controlled trial comparing alternative regimens for escalating (COMPARE) treatment of intermediate and high-risk oropharyngeal cancer with reflections on the complications of introducing a new experimental arm. Trials. 2015;16 Suppl 2:O16. ID - ref141 ER - TY - JOUR AU - Gerety, E. L. AU - Lawrence, E. M. AU - Wason, J. AU - Yan, H. AU - Hilborne, S. AU - Buscombe, J. PY - 2015 DA - 2015// TI - Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv289 DO - 10.1093/annonc/mdv289 ID - Gerety2015 ER - TY - JOUR AU - Ho, T. W. AU - Pearlman, E. AU - Lewis, D. AU - Hämäläinen, M. AU - Connor, K. AU - Michelson, D. PY - 2012 DA - 2012// TI - Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design JO - Cephalalgia VL - 32 UR - https://doi.org/10.1177/0333102412451358 DO - 10.1177/0333102412451358 ID - Ho2012 ER - TY - JOUR AU - Wang, S. J. AU - Hung, H. M. J. PY - 2013 DA - 2013// TI - Adaptive enrichment with subpopulation selection at interim: methodologies, applications and design considerations JO - Contemp Clin Trials VL - 36 UR - https://doi.org/10.1016/j.cct.2013.09.008 DO - 10.1016/j.cct.2013.09.008 ID - Wang2013 ER - TY - JOUR AU - Kaplan, R. AU - Maughan, T. AU - Crook, A. AU - Fisher, D. AU - Wilson, R. AU - Brown, L. PY - 2013 DA - 2013// TI - Evaluating many treatments and biomarkers in oncology: a new design JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2013.50.7905 DO - 10.1200/JCO.2013.50.7905 ID - Kaplan2013 ER - TY - JOUR AU - Waldron-Lynch, F. AU - Kareclas, P. AU - Irons, K. AU - Walker, N. M. AU - Mander, A. AU - Wicker, L. S. PY - 2014 DA - 2014// TI - Rationale and study design of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial JO - BMJ Open VL - 4 UR - https://doi.org/10.1136/bmjopen-2014-005559 DO - 10.1136/bmjopen-2014-005559 ID - Waldron-Lynch2014 ER - TY - JOUR AU - Biankin, A. V. AU - Piantadosi, S. AU - Hollingsworth, S. J. PY - 2015 DA - 2015// TI - Patient-centric trials for therapeutic development in precision oncology JO - Nature VL - 526 UR - https://doi.org/10.1038/nature15819 DO - 10.1038/nature15819 ID - Biankin2015 ER - TY - JOUR AU - Antoniou, M. AU - Jorgensen, A. L. PY - 2016 DA - 2016// TI - Biomarker-guided adaptive trial designs in phase II and phase III: a methodological review JO - PLoS One VL - 11 UR - https://doi.org/10.1371/journal.pone.0149803 DO - 10.1371/journal.pone.0149803 ID - Antoniou2016 ER - TY - JOUR AU - Warner, P. AU - Weir, C. J. AU - Hansen, C. H. AU - Douglas, A. AU - Madhra, M. AU - Hillier, S. G. PY - 2015 DA - 2015// TI - Low-dose dexamethasone as a treatment for women with heavy menstrual bleeding: protocol for response-adaptive randomised placebo-controlled dose-finding parallel group trial (DexFEM) JO - BMJ Open VL - 5 UR - https://doi.org/10.1136/bmjopen-2014-006837 DO - 10.1136/bmjopen-2014-006837 ID - Warner2015 ER - TY - JOUR AU - Fardipour, P. AU - Littman, G. AU - Burns, D. D. AU - Dragalin, V. AU - Padmanabhan, S. K. AU - Parke, T. PY - 2009 DA - 2009// TI - Planning and executing response-adaptive learn-phase clinical trials: 2. case studies JO - Drug Inf J VL - 43 UR - https://doi.org/10.1177/009286150904300610 DO - 10.1177/009286150904300610 ID - Fardipour2009 ER - TY - JOUR AU - Grieve, A. P. PY - 2017 DA - 2017// TI - Response-adaptive clinical trials: case studies in the medical literature JO - Pharm Stat VL - 16 UR - https://doi.org/10.1002/pst.1778 DO - 10.1002/pst.1778 ID - Grieve2017 ER - TY - JOUR AU - Whitehead, J. AU - Thygesen, H. AU - Jaki, T. AU - Davies, S. AU - Halford, S. AU - Turner, H. PY - 2012 DA - 2012// TI - A novel phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer JO - Stat Med VL - 31 UR - https://doi.org/10.1002/sim.5331 DO - 10.1002/sim.5331 ID - Whitehead2012 ER - TY - STD TI - Khan J, Yap C, Clark R, Fenwick N, Marin D. Practical implementation of an adaptive phase I/II design in chronic myeloid leukaemia: evaluating both efficacy and toxicity using the EffTox design. Trials. 2013;14 Suppl 1:P20. ID - ref153 ER - TY - JOUR AU - Brock, K. AU - Billingham, L. AU - Copland, M. AU - Siddique, S. AU - Sirovica, M. AU - Yap, C. PY - 2017 DA - 2017// TI - Implementing the EffTox dose-finding design in the Matchpoint trial JO - BMC Med Res Methodol VL - 17 UR - https://doi.org/10.1186/s12874-017-0381-x DO - 10.1186/s12874-017-0381-x ID - Brock2017 ER -